A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation
The DOI matches its Crossref record.
Abstract
Daclizumab and basiliximab, engineered human IgG monoclonal antibodies to the interleukin‐2 (IL‐2) receptor α‐subunit, were approved to prevent acute rejection after rnal transplantation. Daclizumab was studied in adult and pediatric renal allograft recipients, liver allograft recipients, and calcineurin‐sparing protocols in renal transplant recipients. Basiliximab was studied in renal allograft recipients and subgroups of recipients of living‐related and cadaveric transplants, and in patients with diabetes mellitus. Both agents reduced acute rejection and were associated with few adverse effects. However, information regarding their long‐term effects on infection, malignancy, chronic rejection, and patient survival must be available before a final decision is made regarding their proper administration. We propose that a likely role the drugs will play in the field of solid organ transplantation is in new protocols that allow sparing of other more toxic immunosuppressive agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
“Clinical data have demonstrated the importance of IL-2 and IL-2Rα in mediating immune disorders; two anti-IL-2Rα antibodies have been approved for use in transplant rejectio”
BackgroundTherapeutic antibodies for human diseases at the dawn of the twenty-first century
Brekke, O. H., & Sandlie, I. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd984 · Cited by 550
Clinical trials of antibody therapy
Glennie, M. J., & Johnson, P. W. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01669-8 · Cited by 288
Nanobodies as novel agents for cancer therapy
Revets, H., De Baetselier, P., & Muyldermans, S. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.1.111 · Cited by 254
abYsis: integrated antibody sequence and structure-management, analysis, and prediction
Swindells, M. B., Porter, C. T., Couch, M., Hurst, J., Abhinandan, K. R., Nielsen, J. H., Macindoe, G., Hetherington, J., & Martin, A. C. R. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.08.019 · Cited by 184
Metadata
- Authors
- Berard, J. L., Velez, R. L., Freeman, R. B., & Tsunoda, S. M.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 1999-10
- Volume
- 19
- Issue
- 10
- Pages
- 1127-1137
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2154036132
- Cited by
- 67
- References
- 0
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation. https://app.cochat.ai/papers/10.1592/phco.19.15.1127.30582
- The paper
- Berard, J. L., Velez, R. L., Freeman, R. B., & Tsunoda, S. M. (1999). A Review of Interleukin‐2 Receptor Antagonists in Solid Organ Transplantation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1592/phco.19.15.1127.30582
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.